This site is intended for healthcare professionals
Anti-integrins in IBD Learning Zone

Welcome

Read time: 140 mins
The growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has provided a variety of novel therapeutic targets. Apart from the tumour necrosis factor-α mediated pathway, which is the target of the first marketed biologics in this indication, several other pathways are involved in triggering an inflammatory response.

ECCO 2020 - Optimisation of the treat-to-target approach looks to be a promising step towards improving quality of life and disease outcomes in patients with ulcerative colitis (UC) and Crohn’s disease (CD), and as such, many experts are pushing for the introduction of more stringent treatment targets. Watch expert faculty provide valuable insight on key issues.

Marketed therapies for the management of moderately to severely active IBD inhibit cytokine signalling pathways or target leukocyte trafficking.

Figure 1: Marketed therapies for the management of moderately to severely active IBD inhibit cytokine signalling pathways or target leukocyte trafficking. Anti-p40; anti-p40 antibodies; Anti-TNFs, anti-tumour necrosis factors; IBD, inflammatory bowel disease; ICAM-1, intracellular cell adhesion molecule; IL-12R, interleukin-12 receptor; IL-23R, interleukin-23 receptor; JAK, Janus kinase; MAdCAM-1, mucosal cell adhesion molecule; TNFα, tumour necrosis factorα; TNFR, tumour necrosis factor receptor; VCAM-1, vascular cell adhesion molecule (adapted from Cimzia® Summary of Product Characteristics, 2014; Entyvio® Summary of Product Characteristics, 2014; Humira® Summary of Product Characteristics, 2008; Remicade® Summary of Product Characteristics, 2009; Stelara® Summary of Product Characteristics, 2013; Simponi® Summary of Product Characteristics, 2014; Tysabri® Prescribing Information, 2016; Xeljanz® Summary of Product Characteristics, 2017).

In both ulcerative colitis and Crohn’s disease, the invasion of the intestinal mucosa by leukocytes is now an important clinical focus (Park & Jeen, 2018). Anti-integrin therapies which block the action of integrins and endothelial cell adhesion molecules include natalizumab and also vedolizumab which targets trafficking of leukocytes. Find out more about their mechanisms of action, explore the relevant study data and review recent data shared at Congresses.

Register free for full access to medthority.com